ES2075845T3 - 3,5-di-terc-butil-4-hidroxifenil-1,3,4-tiadiazoles, oxadiazoles y 3,5-di-terc-butil-4-hidroxifenil-1,2,4-tiadiazoles, oxadiazoles y triazoles como agentes antiinflamatorios. - Google Patents

3,5-di-terc-butil-4-hidroxifenil-1,3,4-tiadiazoles, oxadiazoles y 3,5-di-terc-butil-4-hidroxifenil-1,2,4-tiadiazoles, oxadiazoles y triazoles como agentes antiinflamatorios.

Info

Publication number
ES2075845T3
ES2075845T3 ES89121896T ES89121896T ES2075845T3 ES 2075845 T3 ES2075845 T3 ES 2075845T3 ES 89121896 T ES89121896 T ES 89121896T ES 89121896 T ES89121896 T ES 89121896T ES 2075845 T3 ES2075845 T3 ES 2075845T3
Authority
ES
Spain
Prior art keywords
oxadiazoles
tiadiazoles
hidroxifenil
butil
terc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89121896T
Other languages
English (en)
Inventor
David Thomas Connor
Catherine Rose Kostlan
Michael David Mullican
Michael William Wilson
Daniel Lee Flynn
Gary Paul Shrum
Paul Charles Unangst
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Application granted granted Critical
Publication of ES2075845T3 publication Critical patent/ES2075845T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/13—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

EL PRESENTE INVENTO ES UN NUEVO COMPUESTO QUE COMPRENDE 3,5,-DI-TERCIARIO-BUTIL-4-HIDROXIFENIL SUSTITUIDO 1,2,4- Y 1,3,4-TRIDAZOLAS Y OXADIAZOLAS, Y 1,2,4 -TRIAZOLAS, Y LAS SALES DE BASE Y ADICCIONES FARMACEUTICAMENTE ACEPTABLES DE LOS MISMOS. TAMBIEN SE PRESENTAN COMPUESTOS FARMACEUTICOS Y METODO PARA EL USO DE LOS MISMOS. LOS COMPUESTOS DEL INVENTO TIENE ACTIVIDAD COMO INHIBIDORES DE 5-LIPOXIGENASA Y / O CICLOXIGENASA CONSTITUYENDO UN TRATAMIENTO DE LAS CONDICIONES ACEPTADAS MEDIANTE TAL INHIBICION QUE INCLUYEN LA INFLAMACION, ARTRITIS, DOLOR, LA FIEBRE Y SIMILARES.
ES89121896T 1988-11-29 1989-11-28 3,5-di-terc-butil-4-hidroxifenil-1,3,4-tiadiazoles, oxadiazoles y 3,5-di-terc-butil-4-hidroxifenil-1,2,4-tiadiazoles, oxadiazoles y triazoles como agentes antiinflamatorios. Expired - Lifetime ES2075845T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27717188A 1988-11-29 1988-11-29
US42681489A 1989-10-30 1989-10-30

Publications (1)

Publication Number Publication Date
ES2075845T3 true ES2075845T3 (es) 1995-10-16

Family

ID=26958349

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89121896T Expired - Lifetime ES2075845T3 (es) 1988-11-29 1989-11-28 3,5-di-terc-butil-4-hidroxifenil-1,3,4-tiadiazoles, oxadiazoles y 3,5-di-terc-butil-4-hidroxifenil-1,2,4-tiadiazoles, oxadiazoles y triazoles como agentes antiinflamatorios.

Country Status (16)

Country Link
EP (1) EP0371438B1 (es)
JP (1) JP2821208B2 (es)
KR (1) KR970004914B1 (es)
AT (1) ATE127116T1 (es)
AU (1) AU631385B2 (es)
CA (1) CA2004154C (es)
DE (1) DE68924044T2 (es)
DK (1) DK599789A (es)
ES (1) ES2075845T3 (es)
FI (1) FI93954C (es)
GR (1) GR3017688T3 (es)
IE (1) IE68850B1 (es)
NO (1) NO178623C (es)
NZ (1) NZ231534A (es)
PH (1) PH27025A (es)
PT (1) PT92451B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5102897A (en) * 1990-03-27 1992-04-07 Warner-Lambert Company 3,5-ditertiarybutyl-4-hydroxyphenyl, 1,3,4-thiadiazoles and oxadiazoles linked by carbon, oxygen, and sulfur residues
US5114958A (en) * 1991-05-09 1992-05-19 Warner-Lambert Company 1,2,4-oxadiazole and 1,2,4-thiadiazole derivatives of fenamates as antiinflammatory agents
US5143929A (en) * 1991-05-09 1992-09-01 Warner-Lambert Company 2-substituted thiazolidinone, oxazolidinone, and imidazolidinone derivatives of fenamates as antiinflammatory agents
EP0595546B1 (en) * 1992-10-28 1996-03-20 Shionogi & Co., Ltd. Benzylidene derivatives
FI951367A (fi) * 1994-03-28 1995-09-29 Japan Energy Corp Puriinijohdannaiset ja tulehdustautien tukahduttajat (suppressantit)
WO1996022772A1 (en) * 1995-01-23 1996-08-01 Eli Lilly And Company Method for treating multiple sclerosis
WO1999020617A1 (en) * 1997-10-21 1999-04-29 Active Biotech Ab Antiinflammatory thiadiazolyl ureas which act as lfa-1 and mac-1 inhibitors
UA66401C2 (en) 1998-12-02 2004-05-17 Sentor Pharmaceuticals Inc 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical composition containing the same
US6730700B2 (en) 1998-12-02 2004-05-04 Renovis, Inc. 3,4,5,-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same
US6492527B1 (en) * 1999-10-13 2002-12-10 Fmc Corporation Process to prepare aryltriazolinones and novel intermediates thereto
EP1440968A1 (en) * 1999-10-13 2004-07-28 Fmc Corporation Process to prepare aryltriazolinones and novel intermediates thereto
SE0301232D0 (sv) * 2003-04-25 2003-04-25 Astrazeneca Ab Novel use
FR2883745A1 (fr) * 2005-04-01 2006-10-06 Galderma Res & Dev Nouveaux inhibiteurs de la tyrosinase et leur utilisation en medecine humaine ainsi qu'en cosmetique
FR2883875A1 (fr) * 2005-04-01 2006-10-06 Galderma Res & Dev Nouveaux inhibiteurs de la tyrosinase, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
WO2006103345A1 (fr) * 2005-04-01 2006-10-05 Galderma Research & Development Inhibiteurs de la tyrosinase et leur utilisation pour traiter les desordres hyperpigmentaires
WO2006103119A2 (en) * 2005-04-01 2006-10-05 Galderma Research & Development Tyrosinase inhibitors, process for the preparation thereof and use thereof in human medicine and also in cosmetics
DE102008038220A1 (de) * 2008-08-18 2010-02-25 Merck Patent Gmbh Oxadiazolderivate
WO2011028651A1 (en) * 2009-09-01 2011-03-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of human 15-lipoxygenase-1
US8580805B2 (en) * 2010-08-31 2013-11-12 Hubert Maehr Pyrimidine carboxamide derivatives
CN103102322B (zh) 2011-11-14 2016-02-24 上海交通大学 噁唑类化合物及其制备方法、药物组合物及其用途
CL2012003253A1 (es) * 2012-11-22 2013-01-11 Univ Concepcion Compuestos derivados de 1,3,4-tiadiazol alquilamidas y de chalconas, antagonistas del receptor trpv-1; uso de los compuestos para tratar el dolor cronico.
GB201810581D0 (en) 2018-06-28 2018-08-15 Ctxt Pty Ltd Compounds
ES2969616T3 (es) 2019-06-18 2024-05-21 Pfizer Derivados de benzisoxazol sulfonamida

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2215949B1 (es) * 1973-02-01 1976-07-02 Delalande Sa
US4212970A (en) * 1977-11-28 1980-07-15 Fuji Photo Film Co., Ltd. 2-Halomethyl-5-vinyl-1,3,4-oxadiazole compounds
JPS58150576A (ja) * 1982-03-03 1983-09-07 Sumitomo Chem Co Ltd 新規な１，２，４−オキサジアゾ−ル誘導体
DE3302120A1 (de) * 1983-01-22 1984-07-26 Bayer Ag, 5090 Leverkusen (+)-antipode des (e)-1-cyclohexyl-4,4-dimethyl-3-hydroxy-2-(1,2,4-triazol-1-yl)-pent-1-ens
IL79648A (en) * 1985-08-09 1991-12-12 Lilly Co Eli Pharmaceutical anti-inflammatory and ischemia preventing compositions containing di-t-butylphenol derivatives,some such novel compounds and process for their preparation
US4743606A (en) * 1986-03-25 1988-05-10 Boehringer Ingelheim Pharmaceuticals, Inc. 3-[2-(3',5'-di-t-butyl-4'-hydroxyphenyl)ethenyl]pyridine having anti-inflammatory and anti-arthritic properties
US4758578A (en) * 1987-01-29 1988-07-19 Hoechst Roussel Pharmaceuticals, Inc. Arylthiadiazolylsulfonamides, pharmaceutical compositions and use
JPH03501731A (ja) * 1987-12-31 1991-04-18 スミスクライン・ベックマン・コーポレイション ４‐アラルキル‐５‐置換‐１，２，４‐トリアゾール‐５‐チオール類

Also Published As

Publication number Publication date
IE68850B1 (en) 1996-07-24
KR900007818A (ko) 1990-06-02
JP2821208B2 (ja) 1998-11-05
NZ231534A (en) 1992-02-25
DE68924044D1 (de) 1995-10-05
NO178623B (no) 1996-01-22
EP0371438A3 (en) 1991-03-27
AU631385B2 (en) 1992-11-26
DK599789A (da) 1990-05-30
DE68924044T2 (de) 1996-02-15
DK599789D0 (da) 1989-11-28
KR970004914B1 (ko) 1997-04-08
FI93954C (fi) 1995-06-26
PH27025A (en) 1993-02-01
NO894742D0 (no) 1989-11-28
PT92451A (pt) 1990-05-31
IE893785L (en) 1990-05-29
NO178623C (no) 1996-05-02
CA2004154A1 (en) 1990-05-29
EP0371438B1 (en) 1995-08-30
GR3017688T3 (en) 1996-01-31
PT92451B (pt) 1995-07-18
NO894742L (no) 1990-05-30
ATE127116T1 (de) 1995-09-15
AU4562589A (en) 1990-06-21
EP0371438A2 (en) 1990-06-06
CA2004154C (en) 1997-10-07
FI93954B (fi) 1995-03-15
FI895669A0 (fi) 1989-11-27
JPH02270865A (ja) 1990-11-05

Similar Documents

Publication Publication Date Title
ES2075845T3 (es) 3,5-di-terc-butil-4-hidroxifenil-1,3,4-tiadiazoles, oxadiazoles y 3,5-di-terc-butil-4-hidroxifenil-1,2,4-tiadiazoles, oxadiazoles y triazoles como agentes antiinflamatorios.
SE8804036L (sv) Ny anvaendning av 11,28-dioxa-4-azatricklo (22.3.1.04.9)-oktakos-18-en-derivat och farmaceutiska kompositioner innehaallande desamma
SE9604786D0 (sv) New compounds
MY107341A (en) Novel hydroxamic acid and n-hydroxyurea derivatives and their use
DE69402173D1 (de) Hemmung von Thrombin
ES8707947A1 (es) Un procedimiento para la preparacion de acidos 3-hidroxifenoxialquilenheterociclilcarboxilicos.
ATE187642T1 (de) Verwendund von norastemizol zur behandlung der allergischen rhinitis
PT652874E (pt) 2-heterociclico-5-hidroxi-1,3-pirimidinas uteis como agentes anti-inflamatorios
CA2099867A1 (en) 2-substituted-4,6-di-tertiary-butyl-5-hydroxy-1,3-pyrimidines useful as antiinflammatory agents
ATE89725T1 (de) 3-substituierte 2-oxindol-1-carboxamid-derivate zur hemmung der aktivitaet der t-zellen.
ATE16150T1 (de) Xanthinoxydasehemmer und verwendung von benztriazinderivaten.
ATE75399T1 (de) Therapeutikum zur behandlung von magengeschwueren.
NO872812L (no) 4-nitrogensubstituerte isokinolinolforbindelser med terapeutisk aktivitet og fremgangsmŸte for deres fremstilling.
FI840352A (fi) Fungicida triazolfoereningar.
ATE95697T1 (de) Uricosuretische zusammensetzung.
DE3878186D1 (de) Azolverbindungen.
IT8047950A0 (it) Composizioni farmaceutiche impiegabili per il trattamento dell'ipertensione

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 371438

Country of ref document: ES